Dupixent 300 mg/2mL (Dupilumab INJECTION, SOLUTION) 300 mg/2mL

Dupixent 300 mg/2mL is a biologic injection that blocks the IL-4 and IL-13 inflammation pathway, which is involved in various type 2 allergic conditions. It is used to treat the following conditions:

• Atopic dermatitis: Reduces symptoms such as itching, redness, and swelling in patients with moderate-to-severe eczema.
• Asthma: Used as an add-on maintenance treatment for patients with uncontrolled asthma.
• Chronic rhinosinusitis with nasal polyps: Helps to reduce the size of nasal polyps and improve symptoms.
• Eosinophilic oesophagitis: Manages inflammation in the esophagus caused by eosinophils.
• Prurigo nodularis: Alleviates itching and skin lesions associated with this condition.

• Dupilumab works by binding to the IL-4 receptor alpha subunit, which blocks the signaling of both interleukin-4 (IL-4) and interleukin-13 (IL-13). This action reduces type 2 inflammatory responses, which are central to conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. By inhibiting these pathways, dupilumab helps to alleviate symptoms and manage the underlying inflammation.

Dupixent 300 mg/2mL may cause various side effects, ranging from common to serious or rare reactions.

Common Side Effects

• Injection site reactions, including erythema, edema, pruritus, pain, and swelling.
• Conjunctivitis and allergic conjunctivitis, especially in patients with atopic dermatitis.
• Oral herpes and eosinophilia, which is usually transient and asymptomatic.
• Arthalgia and blistering or hematoma at the injection site.
• Induration and dermatitis at the injection site.
• Rash at the injection site.

Serious or Rare Side Effects

• Hypersensitivity reactions, including anaphylaxis and serum sickness, which are rare.
• Keratitis, which can be serious and requires medical attention.
• Eosinophilic conditions, such as vasculitis or eosinophilic pneumonia, sometimes after oral steroid taper.

Dupixent 300 mg/2mL should be used with caution and under the supervision of a healthcare professional. Important precautions include:

• Inform your healthcare provider about any allergies or medical conditions before starting treatment.
• Avoid live vaccines during treatment with dupilumab.
• Patients with helminth infections should be treated before initiating dupilumab.
• Monitor for signs of hypersensitivity reactions, including anaphylaxis and serum sickness.
• Regularly check for signs of keratitis and eosinophilic conditions.
• Store at 2-8°C: Keep refrigerated, protect from light, and do not freeze or shake.

Dupixent 300 mg/2mL may interact with other medications, requiring careful monitoring or avoidance of certain combinations.

Major Interactions (Avoid)

• Live vaccines: Avoid administration of live and live attenuated vaccines during treatment with dupilumab.
• Immunosuppressive therapies: Caution is advised when combining with other immunosuppressive therapies.

Moderate Interactions (Monitor Closely)

• Oral corticosteroids: Monitor for signs of eosinophilic conditions when tapering oral corticosteroids.
• Other biologic therapies: Monitor for increased risk of infections or other adverse effects when used in combination with other biologic therapies.
• Immunomodulators: Monitor for signs of increased immunosuppression or infections.